Sarepta Therapeutics (SRPT) Gets Boost by FDA Data Request; United Natural Foods (UNFI) Posts Profit Above-Consensus


Shares of Sarepta Therapeutics, Inc. (Nasdaq:SRPT) soared more than 25% in the extended session Monday after the company said that the U.S. Food and Drug Administration (FDA) requested – as part of an ongoing evaluation – dystrophin data from the confirmatory study of its Duchenne Muscular Dystrophy drug candidate eteplirsen

SRPT stock closed in positive territory by 3.08% (or $0.48) at $16.05, with a total volume of 4,659,725 shares traded on Monday

Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics, has 45.77M Shares Outstanding, Market Capitalization (intraday) of $734.57M and SRPT stock one-year range is between $8.00 and $41.97 per share



United Natural Foods, Inc. (Nasdaq:UNFI) shares climbed over 10% in after-hours trading Monday as the company delivered in its financial results quarterly profit above Wall Street analysts’ expectations

For its third quarter fiscal 2016, the natural foods distributor posted net sales of $2.13 billion and net income of $38.3 million or $0.76 per diluted share, topping the Capital IQ Consensus estimate of $0.66 earnings per share for the period

United Natural Foods said that it expects to deliver full-year fiscal 2016 net sales of about $8.46 billion to $8.50 billion and adjusted net income of between $2.47 and $2.53 per diluted share, also surpassing the Capital IQ Consensus Estimate of $2.38 earnings per share on revenues of $8.41 billion for tghe period

UNFI stock finished the regular session at $38.83, up $0.22 (or +0.57%) with a total volume of 1,071,010 shares traded during the day

United Natural Foods, which distributes and retails natural, organic, and specialty foods and non-food products in the United States and Canada, has 50.33M Shares Outstanding, Market Capitalization (intraday) of $1.95B and UNFI stock 52-week range is from $29.75 to $64.90 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at